Novo Nordisk A/S (0TDD.L)
Makes insulin and weight-loss drugs for diabetes and obesity treatment worldwide.
$51.63+0.01%
StockGlow Score
Bearish
BearishBullish
1 year ago+8.1%
The outlook
Novo Nordisk is trading near its 52-week low, well below both its 50- and 200-day moving averages, reflecting a sharp downtrend. The stock shows a bearish lean in current sentiment, with analyst coverage sparse. The unusually low trailing P/E warrants scrutiny into the company's recent earnings metrics.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Market cap
—
52-wk high
$142.93
52-wk low
$50.66
50-day avg
$116.39
200-day avg
$97.55
Trailing P/E
0.2